Find Clinical Trial

Clinical long-term effects of Valdoxan® (25 or 50 mg) in depressed patients. Clinical, national, interventional, phase IV, multicentre, open study. Valdoxan® D-EXTENSION Study

← Back
Study Phase

Phase 4

Therapeutic Area

Neuropsychiatric Diseases

IndicationMajor Depressive Disorder
SponsorEUTHERAPIE / Les Laboratoires Servier
Active substance/
Medical device


Active Substance CodeS020098
Protocol CodeDM4-20098-112
EudraCT Code2009-010112-15

Documents and links

Results summary READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

© 2023 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.